Drawing for ENOBLE

USPTO serial 97375018

ENOBLE

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
AWRICH, ELLEN
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with ENOBLE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maury M. Tepper, III

Maury M. Tepper, III TEPPER & EYSTER, PLLC3724 BENSON DRRALEIGH, NC 27609-7321United States

Goods and services

ClassDescriptionStatusFirst use
009Downloadable computer software used for data processing; Downloadable computer application software for data processing; downloadable computer software for data processing; electronic apparatus and electronic equipment, namely, computer hardware and computer peripherals, downloadable software, downloadable computer programs and systems comprised of computer hardware and computer peripherals, all for the capture, collection, conversion, analysis, communication, processing, receiving, recording, storage and/or transmission of data, images and information; mechanisms for data processing equipment, namely, data processors and computers; data sets, recorded or downloadable, in the field of medical research data, patient medical information and clinical trial data; electronic apparatus and electronic equipment, namely, computer hardware and computer peripherals, downloadable software, downloadable computer programs and systems comprised of computer hardware and computer peripherals, all for the conversion, analysis, processing, storage and transmission of artificial intelligence data; downloadable artificial intelligence and machine learning software for statistical analysis, consultancy and reporting; downloadable software for performing and interpreting analytics research in the fields of public health, healthcare, pharmaceuticals, biotechnology, biomedical research and development, clinical trials; downloadable computer software for database integration; downloadable computer software for creating searchable databases of information and data; downloadable computer software used for searching electronic computer databases of medical research data, clinical trials data, patient information and medical industry stakeholders information; downloadable computer software for accessing data and information related to patient medical information, medical research data and clinical trial data and for controlling and managing data and information related to medical research data, patient medical information and clinical trial data; downloadable computer software platforms for integrating clinical and non-clinical patient and medical data; downloadable computer software to enable sharing of data and comments among users; data communication apparatus, namely, computer hardware, computer peripherals, and downloadable computer software, used for transmitting data and information to databases; downloadable software in the nature of mobile applications, used for transmitting data and information to databases; downloadable cloud-based software for data collection, data research, data management, and data analysis; all the aforesaid goods to be used in the medical and healthcare fieldsACTIVE—
035Collection, systematization, compilation and analysis of business data and information into computer databases; business analysis and consultancy and statistical analysis of healthcare data, biomedical research and clinical trial data for business purposes; database management; compilation of information into computer databases in the fields of medical research, public health, healthcare, biomedicine, biotechnology, pharmaceuticals, clinical trials, pharmacoepidemiologic research and evaluating outcomes; professional business analysis and consultancy and statistical analysis in the fields of medical research, public health, healthcare, pharmaceuticals, biotechnology, biomedical research and developments, clinical trials, pharmacoepidemiologic research and research evaluating outcomes for business purposes; business consulting and management in the field medical research, namely, management and compilation of computerized databases in the field of medical research data and clinical trials for business purposes; Office functions in the nature of data search in computer files for others; registration of written communications and data in the fields of medical research and healthcare; updating and maintenance of data in computer databases; all the aforesaid services to be provided in the medical and healthcare fieldsACTIVE—
038Telecommunications, namely, electronic data transmission; electrical and electronic communications, namely, electronic data transmission; providing access to databases; electronic transmission of data; all the aforesaid services to be provided in the medical and healthcare fieldsACTIVE—
042Software as a Service (SAAS) services featuring software for collecting and analyzing medical and healthcare data; platform as a service featuring computer software platforms for accessing database with information, data, statistics, insights, metrics, profiles, analytics and intelligence on public health, healthcare, biomedicine, pharmaceuticals, clinical trials, pharmacoepidemiologic research and evaluating outcomes; cloud computing featuring software for use in extracting, analyzing, standardizing and cleaning clinical, medical and healthcare data; providing a website featuring technology that enables users to share and process data for use in the fields of scientific research, medical and healthcare fields; a computerized knowledge exchange website, namely, providing a website featuring technology that enables exchanging and analyzing of medical, scientific and clinical trial information by users, including segregated, dispersed or disparate data, which uses big data analytics, machine learning and natural language processing; database design and development; bioinformatics interpretation of health data; compiling data for research purposes in the field of medical science and medical consultancy; design, development, installation, upgrading and maintenance of computer software; design of information graphics and data visualization materials; providing online non-downloadable computer software for use in data processing in the medical and healthcare fields; providing online non-downloadable computer application software for use in data processing in the medical and healthcare fields; data conversion of electronic information; providing temporary use of non-downloadable software used for performing and interpreting analytics research in the fields of medical research, public health, healthcare, biomedicine, biotechnology, pharmaceuticals, clinical trials, pharmacoepidemiologic research data; providing temporary use of online non-downloadable software for the capture, collection, conversion, analysis, communication, processing, receiving, recording, storage and/or transmission of data, images and information of health data; scientific data processing analysis services; providing temporary use of non-downloadable software to enable sharing of data and comments among users; scientific and technological services, namely, research and development of new products, and scientific research and industrial design relating thereto; industrial analysis, industrial research and industrial design services, namely, research and development of new products; quality control for others; and authentication services, namely, testing of pharmaceuticals for authentication purposes; electronic data storage; testing, inspection and research of pharmaceuticals and providing advice and information relating thereto; all the aforesaid services to be provided in the medical and healthcare fieldsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Sep 14, 2026MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Sep 14, 2026ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jun 23, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jun 22, 2026EX5GSOU EXTENSION 5 GRANTED—
Jun 18, 2026AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Feb 4, 2026EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 3, 2026EXT5SOU EXTENSION 5 FILED—
Aug 2, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 1, 2025EX4GSOU EXTENSION 4 GRANTED—
Aug 1, 2025EXT4SOU EXTENSION 4 FILED—
Aug 1, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 5, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 5, 2025EX3GSOU EXTENSION 3 GRANTED—
Feb 4, 2025EXT3SOU EXTENSION 3 FILED—
Feb 4, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Aug 5, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 5, 2024EX2GSOU EXTENSION 2 GRANTED—
Aug 5, 2024EXT2SOU EXTENSION 2 FILED—
Aug 5, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 8, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 6, 2024EX1GSOU EXTENSION 1 GRANTED—
Feb 6, 2024EXT1SOU EXTENSION 1 FILED—
Feb 6, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Aug 8, 2023NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jun 13, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jun 13, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 24, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
May 5, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 5, 2023XAECEXAMINER'S AMENDMENT ENTERED—
May 5, 2023GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
May 5, 2023GNEAEXAMINERS AMENDMENT E-MAILED—
May 5, 2023CNEAEXAMINERS AMENDMENT -WRITTEN—
May 4, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 4, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 4, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 8, 2023GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 8, 2023GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 8, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 8, 2023DOCKASSIGNED TO EXAMINER—
Apr 27, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 25, 2022NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance